Anika receives the ace award for cutting-edge innovation for tactoset® injectable bone substitute from the american orthopedic society for sports medicine

Bedford, mass., july 27, 2022 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the accelerating the cutting edge (ace) award from the american orthopaedic society for sports medicine (aossm) for tactoset® injectable bone substitute for hardware augmentation. this award highlights the innovative nature of tactoset, a calcium phosphate based, biocompatible bone graft substitute that incorporates anika's core hyaluronic acid (ha) technology, and its use to augment hardware and support bone fragments during surgical procedures. the ha component of tactoset makes the product highly flowable, easily injectable and able to interdigitate trabecular bone architecture, such as insufficiency fractures, with overall improved handling characteristics compared to competitive products.
ANIK Ratings Summary
ANIK Quant Ranking